Hydroxyurea is NOT necessary for all patients with essential thrombocythemia—only for those at high risk for thrombotic complications.
Risk-Stratified Treatment Approach
The decision to use hydroxyurea in ET depends entirely on thrombotic risk stratification, not simply on the diagnosis itself. Treatment must be individualized based on validated risk categories 1.
Risk Categories and Treatment Indications
High-Risk Patients (Hydroxyurea IS indicated):
- Age >60 years, OR
- History of thrombosis
- These patients require cytoreductive therapy with hydroxyurea as first-line treatment 1
Intermediate-Risk Patients (Consider hydroxyurea):
- Age >60 years with JAK2 mutation present
- Treatment is optional and should be considered based on additional cardiovascular risk factors 2
Low-Risk Patients (Hydroxyurea NOT indicated):
- Age ≤60 years
- No thrombosis history
- JAK2 mutation present
- Manage with low-dose aspirin only 1
Very Low-Risk Patients (Hydroxyurea NOT indicated):
- Age ≤60 years
- No thrombosis history
- JAK2 wild-type
- Manage with low-dose aspirin only 2
Special Circumstances Requiring Cytoreduction
Even in otherwise low-risk patients, consider hydroxyurea for:
- Platelet count >1,500 × 10⁹/L (bleeding risk from acquired von Willebrand syndrome) 1
- Progressive splenomegaly
- Uncontrolled systemic symptoms
- Well-documented microvascular disturbances 1
Evidence Supporting Risk-Stratified Approach
The landmark Cortelazzo trial demonstrated that hydroxyurea reduces thrombotic complications in high-risk patients compared to no treatment 1, 3. The PT-1 trial further showed that hydroxyurea plus aspirin was superior to anagrelide plus aspirin in preventing arterial thrombosis, major bleeding, and transformation to myelofibrosis 1, 4.
Critically, untreated low-risk patients have thrombosis rates similar to healthy controls, making cytoreductive therapy unnecessary and exposing them to potential toxicities without benefit 1.
Recent real-world data confirms that among older patients who do require treatment, hydroxyurea reduces both thrombotic events (HR 0.51) and mortality (HR 0.52) 5. Additionally, achieving complete hematological response with hydroxyurea in high-risk patients significantly reduces arterial thrombosis risk (HR 0.35) 6.
Important Caveats and Pitfalls
Age Considerations
- In young patients (<40 years), use hydroxyurea cautiously due to concerns about long-term leukemogenic risk 1
- Consider pegylated interferon-α as an alternative first-line agent in this population 7
Leukemogenic Risk
- Hydroxyurea is a human carcinogen with documented risk of secondary leukemia and skin cancer in long-term use 8
- Monitor for secondary malignancies and advise sun protection 8
- Patients receiving multiple cytotoxic agents have significantly higher leukemia risk 1
Monitoring Requirements
- Monitor blood counts at least weekly during therapy 8
- Evaluate for myelosuppression, the most common toxicity 8
- Screen for cutaneous vasculitic toxicities, particularly in patients with prior interferon exposure 8
When to Switch from Hydroxyurea
Change therapy if:
- Intolerance develops (leg ulcers, mucocutaneous manifestations, fever, cytopenia) 1
- Resistance occurs (failure to achieve target platelet count <400 × 10⁹/L) 1
- Consider non-leukemogenic alternatives: anagrelide or interferon-α 1
Aspirin Use
- All patients should receive low-dose aspirin (once daily for high-risk, twice daily for low-risk) unless contraindicated 2
- Screen for acquired von Willebrand syndrome before starting aspirin in patients with extreme thrombocytosis 9, 2
- Withdraw aspirin if major bleeding occurs 1
Bottom Line
Hydroxyurea is the evidence-based first-line cytoreductive therapy for high-risk ET patients (age >60 or thrombosis history), where it demonstrably reduces thrombotic complications and improves survival 1, 3, 4, 5. However, it is not necessary—and potentially harmful—in low-risk patients, who should be managed with aspirin and cardiovascular risk factor modification alone 1. The key is accurate risk stratification at diagnosis and ongoing reassessment, as low-risk patients may transition to high-risk status with aging or thrombotic events 1.